Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition

Abstract

This case suggests that TIO has a dismal prognosis in prostate cancer patients. The clinical oncology community must be aware about such disturbance that can be present in those patients with weakness, bone pain, and hypophosphatemia.

Functional imaging in primary tumour‐induced osteomalacia: relative performance of FDG PET/CT vs somatostatin receptor‐based functional scans: a series of nine patients

“…Except for the elaboration of phosphatonins, the tumours associated with pTIO are remarkably innocuous and harmless per se, although rare associations with malignant neoplasms such as prostatic carcinoma, osteosarcoma and renal cell carcinoma have been reported. 1,8,9 Thus, patients have a unique opportunity of complete cure from their debilitating osteomalacia if these tumours can be localized and excised. However, localizing these often small sized, clinically inapparent tumours that can be present anywhere in the body from head to toes is challenging.…”

Calcium Regulation and Bone Mineral Metabolism in Elderly Patients with Chronic Kidney Disease

“…Mesenchymal tumors are seen in elderly and associated with FGF23 over-production and urine P i wasting, hypophosphatemia, 1,25(OH) 2 D deficiency and osteomalacia [110,111]. Rare forms of FGF23 gain-of-function [112] and loss-of-function [113] mutations can cause familial forms of hyper- or hypophosphatemia, vitamin D alterations and soft-tissue injury.…”

Development of Severe Hypophosphatemia from Acquired Fanconi Syndrome during Treatment with Abiraterone

“…It is most often seen with mesenchymal tumors, though a literature review spanning thirty-four years revealed 24 case reports of this syndrome in patients with metastatic prostate cancer [17]. Two more cases have been reported since [18,19]. Unfortunately, we do not have a baseline serum phosphorous level for the first patient, and he declined follow-up after discontinuing abiraterone.…”